News

Vertex Pharmaceuticals has just announced the US Food and Drug Administration has granted their lead cystic fibrosis treatment Kalydeco® (ivacaftor) a supplemental new drug application (sNDA). Kalydeco was originally formulated to treat CF in patients aged 6 years and older who carry the…

The Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for the commercialization of Quinsair (240 mg) as a therapeutic for adult patients with cystic fibrosis with recurrent infections by Pseudomonas aeruginosa. Cystic Fibrosis (CF) is an inherited disease that is characterized by defective mucus secretions…

A new study entitled “Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices” was published in BMC Microbiology by Juan de Dios Caballero and a group of researchers from Spain. In this study, the authors evaluated the compliance of microbiological procedures…

Clinical-stage biopharmaceutical company N30 Pharmaceuticals, Inc. has named Jon Congleton as the new President and Chief Executive Officer (CEO), as well as a member of the company’s board of directors. Boulder, Colorado-based N30 Pharma is focused on the development of new treatment options for cystic fibrosis (CF), and was the first research company to discover small…

Once dismissed as weakness of human will, chronic depression is increasingly recognized as a legitimate medical problem that is critical to treat. The condition not only affects quality of life, but may also cause additional dire effects on health, specifically in people with cystic fibrosis (CF). German researchers have found that…

Galapagos NV, a developmental stage biotechnology company working on small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics and metabolic diseases, announced it has launched the first Phase I study of GLPG1837, a potentiator formulated as a CFTR-targeted therapy for cystic fibrosis (CF) cases caused by class III/IV mutations. In order…

Lung transplantation patients who are treated with immune-suppressing drugs after surgery to prevent rejection of the lung are susceptible to contracting life-threatening viruses such as cytomegalovirus (CMV). In order to protect against this, lung transplant patients are normally treated with an anti-viral drug called ganciclovir, which decreases mortality caused…

The Cystic Fibrosis Trust recently announced that it would serve as the official charity partner of the British Comedy Awards for their 25th Anniversary special on December 17, 2014. Before the ceremony officially began, a very special video from the Trust made its debut in front of a star-studded…

The rise in bacterial strains that are highly resistant to antibiotics is a growing health concern, as the research community scrambles to discover new alternatives to treating bacterial infections. This concern is particularly heightened in the cystic fibrosis community, where effective antibiotics are crucial in curtailing what could become…

The All-Party Parliamentary Group (APPG) on Cystic Fibrosis was officially launched this Tuesday in the United Kingdom’s House of Commons, with support from politicians and policy makers across the entire political spectrum in the UK in endorsing the Cystic Fibrosis Trust as an effective advocate for fighting the disease…